TABLE 4.
Demographic Characteristics of Patients Randomized to Buprenorphine-Naloxone (N = 234)*
| Variable | |
|---|---|
| Age (yrs) | 37.4 ± 10.5 |
| Gender | |
| Male | 69% |
| Female | 31% |
| Race/Ethnicity | |
| White | 44.9% |
| African-American | 30.8% |
| Latino | 19.2% |
| Multiethnic | 3.8% |
| American Indian | 0.4% |
| Other | 0.9% |
| Employment Status | |
| Full-time | 53.8% |
| Part-time | 20.1% |
| Unemployed | 19.2% |
| Other | 6.9% |
| Duration of Opioid Use (yrs) | 9.7 ± 9.3 |
| Duration of Heroin Use (yrs) | 8.7 ± 9.2 |
| Route of Heroin Use | |
| IV injection | 65.5% |
| Non-IV injection | 3.8% |
| Intranasal | 30.0% |
| Smoke | 1.4% |
| Lifetime Prior Drug Treatments | 2.7 ± 3.7 |
| DSM-IV Other Current Dependence Diagnoses | |
| Nicotine | 29.1% |
| Cocaine | 19.2% |
| Alcohol | 6.0% |
| Cannabis | 5.6% |
| Sedative | 1.7% |
| Amphetamine | 1.3% |
| Hallucinogen | 0.4% |
| Inhalant | 0.4% |
| PCP | 0.0% |
*
Values represent means and standard deviations unless otherwise indicated.